A major new randomized clinical trial has delivered compelling evidence that newer blood-thinning medications can substantially decrease the incidence of serious cardiovascular complications among individuals diagnosed with atrial fibrillation who are categorized as having an intermediate risk of stroke.
The findings, which carry significant implications for global cardiology practice, were unveiled during a dedicated Hot Line session at the prestigious ESC Congress 2026. Simultaneously, the complete data set was published in the New England Journal of Medicine, ensuring immediate visibility and rigorous peer review across the international medical community. According to the trial results, administering oral anticoagulants to this specific patient demographic was associated with a notable decrease in adverse clinical events when evaluated against patients who received no anticoagulant therapy at all.
For decades, the medical management of atrial fibrillation has faced a persistent clinical gray area, particularly concerning patients who do not fit neatly into high-risk categories. Atrial fibrillation, widely recognized as one of the most common forms of cardiac rhythm disorders, disrupts the normal, coordinated beating of the heart’s upper chambers. This disruption can cause blood to pool, significantly increasing the likelihood of dangerous blood clots forming within the heart. If these clots break free, they can travel through the bloodstream to the brain, triggering a debilitating or fatal stroke.
Current international guidelines issued by the European Society of Cardiology strongly advocate for the routine use of oral anticoagulants in patients with atrial fibrillation who are identified as being at high risk for stroke. However, for individuals who fall into an intermediate risk category, the therapeutic path has historically been far less definitive. In current clinical practice guidelines, anticoagulant therapy for these intermediate-risk patients is not mandated; instead, it is listed as an option that "should be considered" by treating physicians on a case-by-case basis.
This enduring clinical uncertainty has largely persisted because historical data relied primarily on observational research, which frequently yielded mixed or conflicting results. Much of that older data was derived from the use of traditional vitamin K antagonist drugs, such as warfarin, which are notoriously difficult to manage due to narrow therapeutic windows, necessary dietary restrictions, and the requirement for frequent blood monitoring.
Principal Investigator Professor Boyoung Joung, affiliated with Yonsei University in Seoul, South Korea, highlighted the limitations of previous literature when discussing the impetus behind the new study. "Evidence from observational studies with anticoagulants, particularly vitamin K antagonists, remains conflicting in those at intermediate risk," Professor Joung explained. "SINGLE-AF was conducted to provide the first evidence from a randomized trial on whether newer direct oral anticoagulants are beneficial in patients with AF at intermediate risk of stroke."
To resolve these long-standing questions, the research team designed and executed the SINGLE-AF trial, structured as an open-label, multi-center study conducted across 18 specialized medical institutions throughout South Korea. The trial successfully enrolled 1,803 individual participants who had been diagnosed with atrial fibrillation and were formally evaluated as having an intermediate risk of stroke. In clinical research terms, this intermediate risk profile was standardized using the well-established CHA2DS2-VASc scoring system, defining the threshold as a score of precisely 1 for male participants and 2 for female participants.
Upon enrollment, the study participants were randomized on a one-to-one ratio into one of two distinct treatment arms. The first group of patients was assigned to receive active direct oral anticoagulant treatment, utilizing either apixaban administered at a dose of 5 milligrams twice daily or rivaroxaban administered at a dose of 20 milligrams once daily, depending on clinical discretion and standard dosing protocols. The second group, serving as the comparator arm, received no anticoagulation therapy whatsoever, reflecting the observational and conservative approach previously common for this intermediate-risk population.
After a rigorous follow-up period lasting 24 months, the investigators conducted a comprehensive analysis of the accumulated clinical data. The results revealed a striking 69% relative reduction in the trial’s primary composite endpoint among the patients who were actively taking direct oral anticoagulants compared with those who received no anticoagulation. This primary endpoint was robustly defined to encompass a wide spectrum of serious clinical outcomes, combining stroke, systemic embolism, major bleeding events, and cardiovascular death.
When looking at the absolute numbers, serious clinical events occurred in only 0.5% of the patients who received direct oral anticoagulant therapy, contrasted with 1.5% of the patients who received no anticoagulant treatment at all. This difference achieved statistical significance, highlighted by a p-value of 0.028, a hazard ratio of 0.31, and a 95% confidence interval ranging from 0.10 to 0.94.
A deeper examination of the specific event types indicated that this impressive risk reduction was driven primarily by a sharp decline in ischemic strokes among the treated cohort. Specifically, an ischemic stroke was documented in just 0.1% of the patients taking direct oral anticoagulants, whereas the incidence rose to 1.1% among the patients in the non-anticoagulation control group.
Crucially, one of the most reassuring safety findings of the SINGLE-AF trial was that the implementation of blood thinner therapy did not trigger a corresponding surge in dangerous bleeding complications. Major bleeding events occurred in only 0.3% of the patients who received direct oral anticoagulant therapy, compared with 0.5% of the patients who did not receive any form of anticoagulation. This demonstrated that the protective cardiovascular benefits of the medications could be achieved without imposing an unacceptable safety penalty in terms of hemorrhage risk.
The publication of these findings is widely expected to exert a considerable influence on future clinical practice guidelines and healthcare policy discussions. By supplying the medical community with high-quality, randomized controlled trial data, the SINGLE-AF study helps close a major knowledge gap regarding a patient population where the true net benefit of anticoagulation therapy has historically remained ambiguous.
Concluding the presentation of the trial data, Professor Joung emphasized the broader regulatory and clinical implications of the research. "We now have evidence from a randomized trial that patients with AF at intermediate stroke risk benefit from DOAC therapy, without an increase in major bleeding," Professor Joung stated. "Data from the SINGLE-AF trial may be used to inform future guideline recommendations and reimbursement policies."